Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
Rheumatol Ther. 2023;10(6):1399–1415 doi: 10.1007/s40744-023-00590-w
Findings from post hoc analyses extend the knowledge base for radiographic benefits of filgotinib in patients with RA.
In practice, poor prognostic factors (PPFs) are used as signals to begin or change therapeutic strategies and may also be used to predict disease course. However, questions remain regarding the utility of PPFs to predict outcomes, including radiographic progression.
To this end, Tanaka, et al. analysed current understanding of benefits associated with filgotinib on radiographic progression and the relevance of baseline factors.
Keywords:
